{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Genetic+Change",
    "query": {
      "condition": "Genetic Change"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 1768,
    "total_pages": 177,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Genetic+Change&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-07-22T07:36:53.256Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00858221",
      "title": "Association of Genes to Resistance to Weight Loss in Obese Patients",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Obesity",
        "Metabolic Syndrome",
        "Dyslipidemia"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "Interleukin Genetics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "21 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "21 Years to 70 Years"
      },
      "enrollment_count": 824,
      "start_date": "2008-08",
      "completion_date": "2009-07",
      "has_results": false,
      "last_update_posted_date": "2009-10-20",
      "last_synced_at": "2026-07-22T07:36:53.256Z",
      "location_count": 1,
      "location_summary": "Danville, Pennsylvania",
      "locations": [
        {
          "city": "Danville",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00858221"
    },
    {
      "nct_id": "NCT00897455",
      "title": "Studying Breast Cancer Risk in Women Who Are BRCA1/BRCA2 Mutation Carriers",
      "overall_status": "UNKNOWN",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "brca1 Mutation Carrier",
        "brca2 Mutation Carrier",
        "Breast Cancer"
      ],
      "interventions": [
        {
          "name": "DNA analysis",
          "type": "GENETIC"
        },
        {
          "name": "mutation analysis",
          "type": "GENETIC"
        },
        {
          "name": "polymorphism analysis",
          "type": "GENETIC"
        },
        {
          "name": "laboratory biomarker analysis",
          "type": "OTHER"
        },
        {
          "name": "evaluation of cancer risk factors",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "GENETIC",
        "OTHER",
        "PROCEDURE"
      ],
      "sponsor": "Gynecologic Oncology Group",
      "sponsor_class": "NETWORK",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "FEMALE",
        "summary": "18 Years to 80 Years · Female only"
      },
      "enrollment_count": 10000,
      "start_date": "2008-04",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2011-03-23",
      "last_synced_at": "2026-07-22T07:36:53.256Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00897455"
    },
    {
      "nct_id": "NCT01578109",
      "title": "Sorafenib Tosylate Before and After Donor Bone Marrow Transplant in Treating Patients With Acute Myeloid Leukemia",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Acute Myeloid Leukemia With FLT3/ITD Mutation"
      ],
      "interventions": [
        {
          "name": "Bone Marrow Transplantation",
          "type": "PROCEDURE"
        },
        {
          "name": "Sorafenib",
          "type": "DRUG"
        },
        {
          "name": "Sorafenib Tosylate",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "DRUG"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 51,
      "start_date": "2012-01-13",
      "completion_date": "2021-03-07",
      "has_results": false,
      "last_update_posted_date": "2024-04-02",
      "last_synced_at": "2026-07-22T07:36:53.256Z",
      "location_count": 2,
      "location_summary": "Baltimore, Maryland",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01578109"
    },
    {
      "nct_id": "NCT05216432",
      "title": "First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, as a Single Agent in Patients With Advanced Solid Tumors and in Combination With Endocrine Therapy +/- a CDK4/6 or CDK4 Inhibitor in Patients With Advanced Solid Tumors or Advanced Breast Cancer",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "PIK3CA Mutation",
        "Solid Tumor, Adult",
        "HER2-negative Breast Cancer",
        "Breast Cancer",
        "Metastatic Breast Cancer",
        "Advanced Breast Cancer",
        "Unresectable Solid Tumor"
      ],
      "interventions": [
        {
          "name": "RLY-2608",
          "type": "DRUG"
        },
        {
          "name": "Fulvestrant",
          "type": "DRUG"
        },
        {
          "name": "Palbociclib 125mg",
          "type": "DRUG"
        },
        {
          "name": "Ribociclib 400mg",
          "type": "DRUG"
        },
        {
          "name": "Ribociclib 600mg",
          "type": "DRUG"
        },
        {
          "name": "PF-07220060 100mg",
          "type": "DRUG"
        },
        {
          "name": "PF-07220060 300 mg",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Relay Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 930,
      "start_date": "2021-12-08",
      "completion_date": "2027-04-30",
      "has_results": false,
      "last_update_posted_date": "2025-09-22",
      "last_synced_at": "2026-07-22T07:36:53.256Z",
      "location_count": 24,
      "location_summary": "Tucson, Arizona • San Diego, California • Denver, Colorado + 17 more",
      "locations": [
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "Orlando",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05216432"
    },
    {
      "nct_id": "NCT06239467",
      "title": "First-in-Human Study of OKI-219 in Advanced Solid Tumors and Advanced Breast Cancer",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Advanced Cancer",
        "Breast Cancer",
        "Advanced Solid Tumors",
        "PI3K Gene Mutation"
      ],
      "interventions": [
        {
          "name": "OKI-219",
          "type": "DRUG"
        },
        {
          "name": "Fulvestrant",
          "type": "DRUG"
        },
        {
          "name": "Trastuzumab",
          "type": "DRUG"
        },
        {
          "name": "Tucatinib",
          "type": "DRUG"
        },
        {
          "name": "Atirmociclib",
          "type": "DRUG"
        },
        {
          "name": "Ribociclib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "OnKure, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 200,
      "start_date": "2024-02-26",
      "completion_date": "2027-08-01",
      "has_results": false,
      "last_update_posted_date": "2026-07-06",
      "last_synced_at": "2026-07-22T07:36:53.256Z",
      "location_count": 12,
      "location_summary": "Encinitas, California • La Jolla, California • Los Angeles, California + 9 more",
      "locations": [
        {
          "city": "Encinitas",
          "state": "California"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Newport Beach",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06239467"
    },
    {
      "nct_id": "NCT04711109",
      "title": "Studying the Effect of Denosumab on Preventing Breast Cancer in Women With a BRCA1 Germline Mutation",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "BRCA1 Mutation",
        "Breast Cancer",
        "Breast Diseases",
        "Breast Neoplasms",
        "Breast Carcinoma",
        "Neoplasms"
      ],
      "interventions": [
        {
          "name": "Denosumab",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Quality-of-Life Assessment",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Alliance for Clinical Trials in Oncology",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "25 Years",
        "maximum_age": "55 Years",
        "sex": "FEMALE",
        "summary": "25 Years to 55 Years · Female only"
      },
      "enrollment_count": 300,
      "start_date": "2023-02-14",
      "completion_date": "2033-12",
      "has_results": false,
      "last_update_posted_date": "2025-04-02",
      "last_synced_at": "2026-07-22T07:36:53.256Z",
      "location_count": 47,
      "location_summary": "Los Angeles, California • San Francisco, California • Aurora, Colorado + 38 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Boulder",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04711109"
    },
    {
      "nct_id": "NCT03745326",
      "title": "Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12D Variant of Mutated RAS in HLA-A*11:01 Patients",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Gastrointestinal Cancer",
        "Pancreatic Cancer",
        "Gastric Cancer",
        "Colon Cancer",
        "Rectal Cancer"
      ],
      "interventions": [
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "Fludarabine",
          "type": "DRUG"
        },
        {
          "name": "Aldesleukin",
          "type": "DRUG"
        },
        {
          "name": "anti-Kirsten rat sarcoma virus (KRAS) Glycine(G) to Aspartic Acid(D) substitution at codon 12 peripheral blood lymphocytes (PBL)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "EKG",
          "type": "DIAGNOSTIC_TEST"
        },
        {
          "name": "CT",
          "type": "DIAGNOSTIC_TEST"
        },
        {
          "name": "MRI",
          "type": "DIAGNOSTIC_TEST"
        },
        {
          "name": "PET",
          "type": "DIAGNOSTIC_TEST"
        },
        {
          "name": "Chest x-ray",
          "type": "DIAGNOSTIC_TEST"
        },
        {
          "name": "Photography",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BIOLOGICAL",
        "DIAGNOSTIC_TEST",
        "OTHER"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "72 Years",
        "sex": "ALL",
        "summary": "18 Years to 72 Years"
      },
      "enrollment_count": 5,
      "start_date": "2019-05-16",
      "completion_date": "2022-08-23",
      "has_results": true,
      "last_update_posted_date": "2026-05-19",
      "last_synced_at": "2026-07-22T07:36:53.256Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03745326"
    },
    {
      "nct_id": "NCT06065748",
      "title": "A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer)",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer"
      ],
      "interventions": [
        {
          "name": "Giredestrant",
          "type": "DRUG"
        },
        {
          "name": "Fulvestrant",
          "type": "DRUG"
        },
        {
          "name": "Abemaciclib",
          "type": "DRUG"
        },
        {
          "name": "Palbociclib",
          "type": "DRUG"
        },
        {
          "name": "Ribociclib",
          "type": "DRUG"
        },
        {
          "name": "LHRH Agonist",
          "type": "DRUG"
        },
        {
          "name": "FoundationOne Liquid CDx Assay (F1LCDx)",
          "type": "DIAGNOSTIC_TEST"
        }
      ],
      "intervention_types": [
        "DRUG",
        "DIAGNOSTIC_TEST"
      ],
      "sponsor": "Hoffmann-La Roche",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 1050,
      "start_date": "2023-12-11",
      "completion_date": "2029-02-12",
      "has_results": false,
      "last_update_posted_date": "2026-07-06",
      "last_synced_at": "2026-07-22T07:36:53.256Z",
      "location_count": 61,
      "location_summary": "Daphne, Alabama • Auburn, California • Glendale, California + 54 more",
      "locations": [
        {
          "city": "Daphne",
          "state": "Alabama"
        },
        {
          "city": "Auburn",
          "state": "California"
        },
        {
          "city": "Glendale",
          "state": "California"
        },
        {
          "city": "Greenbrae",
          "state": "California"
        },
        {
          "city": "Harbor City",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06065748"
    },
    {
      "nct_id": "NCT04182516",
      "title": "Study of NMS-03305293 in Pts with Selected Advanced/Metastatic Solid Tumors",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Advanced/Metastatic Solid Tumors"
      ],
      "interventions": [
        {
          "name": "NMS-03305293",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Nerviano Medical Sciences",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 52,
      "start_date": "2019-11-25",
      "completion_date": "2024-05-16",
      "has_results": false,
      "last_update_posted_date": "2024-09-19",
      "last_synced_at": "2026-07-22T07:36:53.256Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04182516"
    },
    {
      "nct_id": "NCT02476955",
      "title": "Open-label Phase 1b Study of ARQ 092 in Combination With Anastrozole",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Solid Tumors",
        "Ovarian Cancer",
        "Endometrial Cancer"
      ],
      "interventions": [
        {
          "name": "ARQ 092 + carboplatin + paclitaxel (Closed)",
          "type": "DRUG"
        },
        {
          "name": "ARQ 092 + paclitaxel (Closed)",
          "type": "DRUG"
        },
        {
          "name": "ARQ 092 + anastrozole",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 41,
      "start_date": "2015-06-09",
      "completion_date": "2019-05-07",
      "has_results": false,
      "last_update_posted_date": "2020-09-30",
      "last_synced_at": "2026-07-22T07:36:53.256Z",
      "location_count": 5,
      "location_summary": "Grand Rapids, Michigan • New York, New York • Oklahoma City, Oklahoma + 2 more",
      "locations": [
        {
          "city": "Grand Rapids",
          "state": "Michigan"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Oklahoma City",
          "state": "Oklahoma"
        },
        {
          "city": "Houston",
          "state": "Texas"
        },
        {
          "city": "San Antonio",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02476955"
    }
  ]
}